HANSIZHUANG (serplulimab) is the world's first anti-PD-1 mAb for first-line treatment of ES-  SCLC   - HANSIZHUANG (serplulimab) is expected to become the first and only anti-PD-1 ...

Turns out, Walker is one tough dude, though, so “a while,” turned out to be all of two days. All he did between his last post ...

For patients with limited-stage small cell lung cancer, adjuvant therapy with durvalumab leads to significantly longer ...

Daiichi Sankyo and Merck said on Tuesday that their drug, patritumab deruxtecan, met the main goal in a late-stage study in ...

Daiichi Sankyo and Merck said on Tuesday that their drug, patritumab deruxtecan, met the main goal of extending the time some ...

Joshua Ray Walker let fans know this week that Thursday is slated to be a big day for him in his battle against cancer. The ...

Shares of Summit Therapeutics Inc. jumped more than 30% premarket on Monday after the biotech company released late-stage ...

In a historic first, a therapy developed by Summit Therapeutics beat Merck blockbuster Keytruda in late-stage lung cancer ...

Hetronifly in combination with chemotherapy was shown to improve survival of patients with extensive stage small cell lung ...

UK hospital introduces a robotic tool for faster lung cancer diagnosis, expanding early detection from mobile screenings.

Treatment of non-small cell lung cancer (NSCLC) depends on the stage you're in and can include chemotherapy, surgery, ...

Tumor stage, surgical resection rates, and 5-year survival rates were all better among screened patients who had lung cancer.